

FOR IMMEDIATE RELEASE

Contact:Donna RichardsonPhone:216-338-6412Email:donna@collamedixinc.com

CollaMedix Inc. Collaborates with Esteemed Orthopedic Surgeons and Scientists and Appoints David Nolan to Business Advisory Board

CLEVELAND, OHIO, December 2022. CollaMedix[®] Inc. is pleased to announce the distinguished members of our Orthopedic Advisory Board including:



Robert Gillespie, MD Chairman, Orthopedic Advisory Board Chief, Shoulder and Elbow Service, UH Cleveland Medical Center Vice Chair Education and Associate Professor Orthopaedic Residency Program. Program Director, Orthopaedic Surgery, UH Cleveland Medical Center Associate Professor, CWRU School of Medicine



Ozan Akkus, PhD, Inventor

Chief Scientific Officer, CollaMedix Inc. Kent H. Smith Professor of Engineering, CWRU Renowned Collagen Expert and Inventor



Kathleen Derwin, PhD

Vice Chair, Cleveland Clinic Department of Biomedical Engineering Co-Director, Cleveland Clinic Musculoskeletal Research Center Lerner Research Institute, Cleveland Clinic Lerner College of Medicine, CWRU



Joseph lannotti, MD, PhD

Professor, Surgery Cleveland Clinic Lerner College of Medicine, CWRU Chief of Staff, Chief Academic, and Innovations Officer Cleveland Clinic Florida Past Chairman Department Orthopaedic Surgery, Cleveland Clinic 2000 – 2018



James Voos, MD

Head Team Physician, Cleveland Browns, University Hospitals Chair, Department of Orthopaedic Surgery, UH Cleveland Medical Center Professor, CWRU School of Medicine

Dr. Gillespie commented, "I have enjoyed collaborating with Dr. Akkus on his exciting electrocompaction technology. There is significant clinical need for a biologic to augment rotator cuff soft tissue repair and promote healing. I am eager to begin clinical trials with the CollaSleeve. Equally impressive are animal results demonstrating CollaFabric's promise to provide treatment for patients requiring massive gap repair, both with and without added mesenchymal stem cells."

Donna Richardson, Founder, CEO stated: "CollaMedix collaborated with our renowned Orthopedic Advisory Board to develop the CollaSleeve[®], a novel pure collagen triple braided sleeve or scaffold which advances over any suture tape or wire during the standard SpeedBridge rotator cuff repair procedure."



"CollaMedix's novel electrocompacted pure collagen scaffold demonstrates rapid cell infiltration, and a novel pro-regenerative effect. New tenogenic collagen is deposited within the CollaSleeve implant which aligns with native tendon resulting in new tissue formation and strengthening the implant while it slowly resorbs. This response is unlike other products which require the addition of a synthetic material for strength with a potential inflammatory reaction." CollaSleeve is expected to be on the market in 2024.

Ms. Richardson continued: "CollaMedix also welcomes Dave Nolan to our Business Advisory Board. Dave brings significant expertise from his distinguished 25 year career as a recognized leader in the medical technology industry with extensive domestic and international experience in the Orthopedic market. Dave will guide CollaMedix as it prepares to enter the Sports Medicine (\$5B) and Regenerative Medicine markets."



Dave Nolan, Board Advisor Retired Group President, Global Businesses, Zimmer Biomet

CollaMedix[®], a start-up medical device company, develops novel electrocompacted technology and is commercializing products with CollaFabric[®] a pure collagen biofabric or scaffold to promote soft tissue healing. The company is funded by grants from the National Science Foundation, National Institutes of Health and State of Ohio Third Frontier funds.

CollaMedix is seeking syndication investment partners for Series A \$5.5M. If you would like more information contact Donna Richardson, CEO, CollaMedix Inc. at <u>donna@collamedixinc.com</u>; or visit <u>www.collamedixinc.com</u>. A Term Sheet and Offering Memorandum are available for qualified investors.

CollaFabric[®] novel pure collagen medical devices promote soft tissue healing

